This article is more than 5 years old. Information may no longer be current.
Anti-VEGF may improve visual acuity in eyes with polypoidal choroidal vasculopathy
Click Here to Manage Email Alerts
Intravitreal ranibizumab significantly improved visual acuity in eyes with polypoidal choroidal vasculopathy but not in eyes with typical neovascular age-related macular degeneration, a study found.
“We have shown that ranibizumab treatment equivalently reduced retinal exudative changes in patients with typical neovascular AMD or [polypoidal choroidal vasculopathy]. However, visual prognosis after treatment was better in patients with [polypoidal choroidal vasculopathy] compared to those with typical neovascular AMD,” the study authors said.
The retrospective chart review examined medical records of 105 consecutive eyes with AMD that received intravitreal injections of ranibizumab; 49 eyes had typical neovascular AMD and 56 eyes had polypoidal choroidal vasculopathy. Both groups had similar baseline visual acuity.
All eyes were followed up for 1 year after treatment. The authors compared treatment response between eyes with typical neovascular AMD and polypoidal choroidal vasculopathy and assessed correlations between age, lesion size and single nucleotide polymorphisms in CFH and ARMS2 genes.
Visual acuity improved significantly in eyes with polypoidal choroidal vasculopathy but was maintained in eyes with typical neovascular AMD. The between-group differences in visual gains were statistically significant at 3 months (P = .027) and 12 months (P = .044).
Both groups demonstrated similar resolution of serous retinal detachment and retinal edema.
Age and lesion size correlated strongly with visual prognosis in eyes with typical neovascular AMD but not in those with polypoidal choroidal vasculopathy. Data showed no conclusive relationship between the three single nucleotide polymorphisms and response to treatment.
Click Here to Manage Email Alerts